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The human immune system is the product of aeons of evolution, which have brought forth a system that is both delicate in its regulatory mechanisms and powerful in its actions. In order to remain functional and effective, the immune system must be kept in balance. An immune response that is too harsh can do more damage than the infection against which it is mounted would. Immune responses against auto-antigens or harmless allergens can be detrimental if not kept in check. Allergic responses are caused by activation of the immune system upon exposure to external substances that should normally be regarded as harmless and invoke tolerance. Allergy is defined as a hypersensitivity reaction initiated by specific immunologic mechanisms [1]. The atopic diseases that arise in patients with allergy have a prevalence of up to 30% in developed countries and a high overall morbidity [2,3]. A large part of these diseases are attributed to atopic dermatitis (AD) and asthma.

The classic allergy model involves mast-cells with IgE class antibodies against the allergen on their surface. Upon allergen contact, IgE antibodies are cross-linked which causes the mast-cells to burst and release histamine into the surrounding tissue, with the allergic symptoms such as red eyes and wheezing as a result [1,4]. An important factor is the Th1/Th2 balance, largely determining the amount of IgE produced in a patient. A delicate balance between Th1 and Th2 cells exists in the body. Th1 cells primarily secrete IFN-γ, a very potent pro-inflammatory cytokine that can stimulate an array of cells including neutrophils and effector CD8+ T-cells. In addition, it causes a positive feedback-loop via upregulation of IFN- γ production in macrophages which in turn creates an environment in which more CD4+ T-cells maturate into Th1 cells. Th2 cells secrete cytokines such as IL-4 and IL-5 that stimulate B-cells to produce certain antibody types, including IgE, induces eosinophil maturation and the maturation of CD4+ T-cells into Th2 cells. Additionally, Th1 and Th2 cytokines trigger a negative feedback-loop in cells of the opposite phenotype, preventing them from secreting their cytokines. Thus, the environment in which a CD4+ T-cell maturates determines the phenotype it will develop. Furthermore, if the Th1/Th2 balance shifts towards either of the phenotypes, this will not naturally revert to an even distribution due to the positive and negative feedback-loops present. The balance is influenced by external factors such as infections. Upon infection with viruses or intra-cellular bacteria, the balance can tilt towards a Th1 response due to additional secretion of IFN- γ by APCs and T-cells. Infection with parasites can cause a shift towards a Th2 environment [5]. 

As allergy has been associated with high IgE levels in the blood, which is Th2 dependent, it has been considered a condition that arises when the Th1/Th2 balance shifts too much towards Th2. As the percentage of allergic children has been rising for the last decades, while hygiene has been improving in conjunction, it was proposed that these two processes were causally correlated; the Hygiene Hypothesis. The rise in hygiene level supposedly caused children to encounter fewer infections during early childhood, resulting in a shift towards a Th2 environment and a subsequent predisposition to allergy. Many epidemiologic studies have been conducted to investigate the effects of hygiene and infections during childhood on development of allergy, but a clear-cut conclusion has yet to be formed [6]. Interesting details include indications that BCG vaccination is associated with prevalence of atopic diseases [7]. 

CD8+ T-cells have long been regarded as predominant IFN-g producers that did not produce Th2 cytokines. However, when cultured in the presence of IL-2 and IL-4, CD8+ T-cells can produce significant amounts of IL-4 [8]. In fact, CD8+ T-cells can form subsets similar to Th1 and Th2 cells under certain conditions, called Tc1 and Tc2 cells. The subtype differentiation is less drastic compared to Th1 and Th2 cells, as unlike Th2 cells Tc2 cells can still produce some IFN-γ and also produce lower amounts of IL-4 [9]. 

The human immune system has several built-in systems to prevent over-activations of the immune system like in the case of allergy. Immune cells have to receive several stimuli from different cells before they are activated, and even then a single activated cell will not be able to mount an effective response against a target without the help of other activated cells. For instance, T-cells require signals from both the T-cell receptor and co-stimulation via CD28 and DCs require stimulation via TLRs and CD40 to achieve optimal licensing [10]. In addition, there are cells that suppress activation of immune cells, either by secreting suppressive cytokines or suppressing activity using cell-cell contact. The most well-known suppressive cells are the Natural Regulatory T-cells or Natural Tregs. These CD4+FoxP3+ T-cells can suppress immune responses by secreting IL-10 and TGF-β and can also bind cells with the CTLA-4 on their membrane to suppress activity. Several other CD4+ regulatory cells are known, their activity is comparable to that of Natural Tregs but can differ in cytokines secreted and surface-marker expression [11]. In addition to CD4+ T-regs, CD8+FoxP3+ Tregs have also been identified in recent years. They are able to suppress immune responses via cellular and humoral pathways comparable to those influenced by CD4+ Tregs [12]. However, only CD4+ Tregs have been associated with suppression of allergic responses, including supposed correlations between low Treg levels and predisposition for certain atopic diseases [13,14,15]. 

Asthma
As the lungs exist of only a small layer of mucosal tissue, they are vulnerable to infection and damage. The immune system in the lungs is specialized in maintaining gaseous exchange and as such, preventing aberrant inflammation is essential. Alveolar macrophages and a large amount of Tregs make sure that immune responses are only mounted upon encountering pathogens. However, in individuals with genetic predisposition, allergen sensitization can still trigger an immune response, giving rise to asthma [13]. Asthma is an allergic disease mediated by local T-cells in a Th2 cytokine milieu. CD4+ Th2 cells in the lungs of asthma patients produce IL-5, which attracts eosinophils that cause bronchoconstriction by leukotriene production and tissue damage through release of toxic granule proteins  [16,17]. The number of asthma patients is still increasing world-wide and prevalence can be as high as 34.8% in Costa-Rica, followed by Austria with 23.6% [17].  

As most allergic diseases, asthma has long been regarded mainly CD4+ T-cell mediated. However, recent publications have implicated that also CD8+ T-cells play a role in asthma pathogenesis. CD8+ T-cells can indirectly affect the Th1/Th2 balance and IgE production. IFN-γ from CD8+ T-cells induces production of IL-12 and IL-18 by Dendritic Cells (DCs), triggering IFN- γ production by CD4+ T-cells, which results in moderation of the Th2 polarisation. As such, CD8+ T-cell activation can reduce tissue damage in the lungs of asthma patients [18]. This process will be further clarified later on. 

Atopic Dermatitis
AD is a T-cell mediated chronic inflammatory disease caused by hyper-reactivity of the skin to exogenous antigens, primarily from dust mites, often giving rise to eczema. The subsequent loss of skin barrier function due to damage to the stratum corneum can allow normally inhaled allergens and pathogens to penetrate the skin, further aggravating the disease [19]. CD4+ T-cells have always been regarded essential in the development of atopic eczema by producing Th2 cytokines that induce class-switching to IgE antibodies and eosinophil infiltration [20]. AD is different from most other atopic diseases like asthma, where the CD4+ T-cells mostly retain a Th2-cytokine profile, Th1 cells undergo preferential apoptosis and IFN-γ levels are low [21]. Acute AD lesions largely follow this model of Th2 polarisation with high IgE levels. In chronic AD lesions however, the CD4+ T-cells appear to switch to a Th1 cytokine pattern including high IFN-γ secretion levels [22].    

The supposed pivotal role of CD4+ T-cells in AD pathology is mostly based on indirect evidence from AD skin histology and data on PBMCs, instead of looking at the cells in the AD lesions themselves and their function [21,23,24]. In addition, several papers have been published over the years that do describe the presence of CD8+ T-cells in AD lesions and also their ability to induce IgE production and stimulate eosinophil survival [25,26,27]. Though the described percentages of CD8+ T-cells present in lesions are highly variable, it is debatable whether the lack of research into their possible function in AD is justified. Perhaps CD8+ T-cells do indeed play a role in the pathogenesis of AD, as has been shown for asthma, and have these cells been underappreciated for many years. In this thesis, the possibility of an essential function of CD8+ T-cells in AD pathogenesis is discussed. Indications for the existing of pro- and anti-inflammatory roles of CD8+ T-cells in AD pathogenesis will be reviewed, followed by a discussion on implications this has on our view of the disease and therapeutic strategies.  


Pro-inflammatory role of CD8+ T-cells in AD 
Several published papers link a high CD8+ T-cell activity in peripheral blood or AD lesions to increased AD disease severity. Seneviratne et al. describe a correlation between the amount of dust-mite allergen specific CD8+ T-cells present in the peripheral blood of AD patients and disease severity [28]. In addition, it was shown that IFN-γ production by peripheral blood CD8+ T-cells of AD patients is decreased after successful immunotherapy [29]. These data indicate that CD8+ T-cells are not only involved but are actually very important in AD pathogenesis. However, as these data are based on peripheral blood samples, this evidence is only circumstantial.   
    
By depleting CD8+ T-cells in a mouse model for AD, it was shown that CD8+ T-cells are required for AD lesion formation in mice. Mice that were depleted of CD4+ T-cells using the same method showed severe eczema formation upon allergenic sensitization. In addition, adoptive transfer of CD8+ T-cells from sensitized mice into naïve mice lead to rapid lesion formation, indicating that not the CD4+ T-cells but actually the CD8+ T-cells are pivotal in the process of AD lesion formation. It was proposed that the CD8+ T-cells are recruited into the skin the first 24 hours after allergen exposure, causing upregulation of Fas on keratinocytes via IFN-γ and subsequent apoptosis of keratinocytes and infiltration of eosinophils and CD4+ T-cells upon secretion of chemotactic factors by the skin cells, after which the CD8+ T-cells largely disappear [30]. This model could explain the problems encountered with measuring CD8+ T-cells in AD lesions; perhaps the amount of CD8+ T-cells in the lesion peaks early after allergen exposure and decreases shortly thereafter, resulting in varying CD8+ T-cell numbers measured at different time points.   

Though data from mouse models and peripheral blood of AD patients can give indications on the function of CD8+ T-cells in the disease, information on the cells from the lesions themselves is less indirect and more informative. In skin biopsies from human patients with chronic AD, a high percentage of IL-22 producing CD4+ and CD8+ T-cells are present. IL-22 mRNA levels were increased 20-fold compared to healthy controls and the number of CD8+IL-22+ cells present correlated with disease severity. In addition, lowered percentages of IL-17 producing CD4+ T-cells, called Th-17 cells, were found, while the number of IL-17 producing CD8+ T-cells, or Tc-17 cells, in the skin of AD patients did not differ. Material from patients with psoriasis was used as control, as psoriasis skin shows large histological resemblance to AD skin and involves a lot of the same pathways and cytokines [31]. In psoriasis, elevated levels of IL-17 are present, as well as higher levels of IL-23. These two cytokines are thought to contribute to psoriasis pathogenesis by attracting neutrophils to the site of inflammation and inducing expression of anti-microbial peptides [32,33]. IL-22 is also thought to play a role in psoriasis, as it mediates several processes involved in its pathogenesis. Th-17 and Tc-17 cells produce both IL-17 and IL-22, but there are also T-cells that produce only IL-22, know as Th-22 and Tc-22 cells [34]. (Figure 1). The fact that in the chronic AD lesions examined, IL-22 producing T-cells were very frequent, while the IL-17 producing cells were more scarce indicates that perhaps Th-22 and Tc-22 cells are involved in the psoriasis-resembling histological features seen in AD, while the differences between the diseases are due to missing signals from IL-17 cells, probably because they are suppressed by the Th2 cells which are far more frequent in AD when compared to psoriasis. Regardless of the specific mechanisms that are involved, only the CD8+IL-22+ T-cell numbers correlated with disease severity [31], which is a very strong indication for an important role of CD8+ T-cells in AD pathogenesis.    












Though no experiments with T-cells from AD lesions were conducted, only peripheral blood T-cells were used, a study on T-cell receptor excision circles (TRECs) in T-cells from AD and psoriasis patients describes a very novel way of looking at T-cell role in AD. Measurements of TRECs in peripheral blood cells of Psoriasis and AD patients showed that men with AD have less TREC content in their CD8+ T-cells compared to healthy controls and that the TREC content correlated with disease severity and IgE levels [39]. TRECS are small circles of DNA that are excised out of the T-cell genome during TCR generation in the thymus. Every cell that exits the thymus contains a TREC. When a cell with a TREC divides, the TREC does not multiply and is transferred to only one of the daughter cells. Every multiplication further dilutes the TREC content of the daughter cells. Thus, the TREC content of a sample, usually represented in TREC/mL blood or TREC/amount of cells, can be seen as a measure for the combination of thymic output and peripheral proliferation. As it is impossible to differentiate between these two parameters with only data on TREC content, Ki67 measurements are usually conducted in parallel to assess proliferation of the cells. Thymic function can be calculated by correcting the amount of TREC positive cells for the amount of divided Ki67+ cells [40,41]. The fact that TREC content in CD8+ T-cells of male AD patients is supposedly lowered indicates that either thymic output is thwarted or there is increased peripheral proliferation in these patients. No additional measurements were done by the authors except for telomere length assessment, which only provides indirect information in T-cells [42], so a clear conclusion can not be drawn. The authors propose that thymic function in men with AD is thwarted because they have measured highly variable TREC contents in these patients. They conclude that the thymus “fires” bursts of naïve T-cells after disease flares instead of a constant flow of new cells. They even hypothesize that thymic function plays an important role in AD pathogenesis [39]. However, it is equally possible that disease flares trigger additional proliferation of the CD8+ T-cells and thus a lower TREC content is measured, which in time is compensated by the constant flow of new naïve T-cells from the thymus, resulting in a meandering pattern in TREC content measurements. A model in which disease flares trigger additional proliferation of T-cells rather than thwarted thymic function would also make AD more comparable to other chronic inflammatory diseases like psoriasis, rheumatoid arthritis and systemic lupus erythematosus, in which very low TREC levels in both CD4+ and CD8+ T-cells are present but no effect on thymic function is known [39,41,43]. The fact that the correlation between TREC content in CD8+ T-cells and disease severity could only be found in men is not particularly peculiar, as men are known to have lower TREC levels in general and usually develop AD earlier in their life, their CD8+ T-cell populations could be worn down more compared to females [44]. Though the research on TREC contents in AD patients in this paper is not particularly elegant, the chosen approach is rather unique for this field. The apparent correlation between the number of CD8+ T-cells that proliferate or are newly produced and disease severity is another indication that these cells are indeed an important factor in AD pathogenesis, though the fact that the TRECs are measured in peripheral blood makes this evidence relatively circumstantial.    


Anti-inflammatory role of CD8+ T-cells in atopic diseases 
CD4+ T-cells are generally regarded as the most important suppressive cells, but CD8+ T-cells are also able to suppress immune responses. Here, a short overview of literature on suppressive function of CD8+ T-cells in general is given, followed by data on CD8+ T-cell suppression in asthma and mechanisms possibly involved in AD.     

Immune suppression by CD8+ T-cells  
Suppressive CD8+ T-cells were first recognized in 1970 and were called suppressor T-cells at the time [45]. They are currently called CD8+ Tregs. A lack of identified specific surface markers has made research into suppressor cells in general very difficult, causing an inability to determine detailed mechanisms of suppression [46]. Natural CD4+ Tregs express CD25 on their surface and have intracellular FoxP3 expression [11]. However, no definitive surface expression pattern for CD8+ T-cells has been established yet. As in CD4+ Tregs, CD8+ Tregs often express FoxP3 and activation or differentiation markers such as CD25, IL-122 and CD45RC [12,47]. 

CD8+ Tregs deploy three methods of suppression. First, they can induce suppression by cytokine secretion and by cell-cell contact like their CD4+ counterparts do [12]. In addition, CD8+ Tregs are able to reduce inflammation levels by killing target cells; in auto-immune disease settings, they preferentially kill Th1 cells, which can result in a switch to a less pathogenic Th2 response to auto-antigens [48]. The exact mechanism by which CD8+ Tregs kill their targets is not yet clear, though it is possible that they use the same mechanism for this as effector CD8+ T-cells. FasL does not appear to be involved, but perforine could possibly play a role [49]. Papers published on regulatory CD8+ T-cells use auto-immune settings as background for their research [48,50], while data on a possible role in allergy is not yet available. In addition to the function of CD8+ Tregs, effector CD8+ T-cells can regulate immune responses in various other ways. They can produce and secrete various cytokines that can modulate immune responses. IFN-γ is the most apparent cytokine secreted by CD8+ T-cells and has various effects on the immune system, including modulation of APC cytokine secretion, activation of T- B- and NK-cells and some anti-viral effects [51]. Though it is a very potent pro-inflammatory cytokine, it can have indirect anti-inflammatory effects [52].  

Suppression of the immune response in asthma by CD8+ T-cells






Suppression of the immune response in AD by CD8+ T-cells
It is unlikely that the process of immune suppression by CD8+ Tc1-cells as seen in asthma is identical in AD, as asthma differs from AD in various crucial ways. Asthma is very dependent on a Th2 environment and IgE production. Strong IgE sensitization is a very important risk factor for the development of childhood and life-long asthma [55] and in patients with established asthma, serum IgE levels are correlated with disease severity [56]. In AD, especially in chronic lesions, a Th1 environment with high IFN-γ levels secreted by both CD4+ and CD8+ T-cells is common and as such a process in which CD8+ T-cells indirectly modulate the Th1/Th2 balance polarization towards Th1 would probably not decrease at least chronic AD symptoms efficiently. The Th2 environment and high 
IgE levels are still important in the onset and early stages of AD lesions [21], but as it was shown that CD4+ and CD8+ T-cells in the peripheral blood of AD patients are equipotent in inducing IgE production by B-cells and eosinophil survival, it is questionable whether CD8+ T-cells are able to suppress even the early AD stages [57]. However, it is possible that additional IFN-γ decreases AD symptoms in a different way. It was shown that Th2 cytokines IL-4 and IL-13 induce skin barrier destruction by downregulating components of the stratum corneum. In contrast, IFN-γ induces upregulation of these components and thus additional IFN-γ levels could partly restore skin barrier function, decreasing the amount of allergens and pathogens that can invade the skin [19].     

Perhaps CD8+ Tregs are able to suppress inflammation in AD lesions. FoxP3+CD8+ T-cells have been shown to be able to suppress immune responses via humoral and cellular pathways and could be involved in suppression of allergic inflammation [12]. No relevant data on the role of CD8+ Tregs in AD is available yet, but data on CD4+ Treg activity in AD is abundant. Though CD8+ Tregs differ from CD4+ Tregs in mechanisms of suppression and expression of several proteins [47,48], they have enough similarities to justify a comparison. Surprisingly, the amount of CD4+ Tregs in the peripheral blood of AD patients is increased when compared to healthy controls [58]. In AD lesions, CD4+ Tregs are able to proliferate efficiently and CD4+ Tregs isolated from AD lesions are able to suppress proliferation of target cells ex vivo [59]. Thus, it seems that even though there are large amount of functionally potent Tregs present in AD lesions, they are still unable to efficiently regulate the vigorous allergic response. It can be proposed that the amount of immune activation present in AD lesions is so large that the Tregs are unable to suppress it, even though their numbers and potency are large. There is no reason to assume that CD8+ T-cells are able to regulate the response in AD lesions when their CD4+ counterparts are not capable of this, unless they use a different yet unknown strategy for this. 





Even though CD4+ T-cells have been regarded essential in the development and further pathogenesis of AD, an increasing amount of evidence shows that CD8+ T-cells are also very important. Data from the peripheral blood of AD patients indicates that there is a correlation between the amount of allergen-specific CD8+ T-cells and disease severity, as well as a decrease in peripheral blood CD8+ T-cell IFN-γ production upon immunotherapy [28,29]. In a mouse model, CD8+ T-cells are essential for AD lesion formation [30]. Furthermore, the phenotype and TREC levels of CD8+ T-cells present in lesions from AD patients correlate with disease severity [31,35,36]. Several papers show evidence for a pro-inflammatory role of CD8+ T-cells in AD pathogenesis. It is a feasible hypothesis, as CD8+ T-cells are known to be able to induce skin tissue damage, indirectly by activating mast cells [36] and preventing differentiation of skin cells [15], directly by causing upregulation of Fas on skin cells and apoptosis of skin cells via proteases, FasL, Perforin and Granzyme B [21,64].   

However, some evidence for an anti-inflammatory role of CD8+ T-cells in AD exists as well. Data from asthma studies shows an anti-inflammatory role of CD8+ Tc1-cells at the site of infection [18]. It is unlikely that a similar process influences AD pathogenesis, as AD is far less Th2 dependent than asthma [55,56]. It is also improbable that CD8+ Tregs can efficiently suppress AD disease severity, as data on CD4+ Tregs present in AD lesions shows that these cells are unable to decrease inflammation, regardless of their high numbers and potency [59]. It can be argued that CD8+ Tregs could be able to suppress the inflammation in AD lesions using their potential to kill target cells, which CD4+ Tregs do not possess. For instance, killing eosinophils could prevent large scale tissue damage. No evidence for such a mechanism exists however. Furthermore, it is possible that CD8+ T-cells are able to partly restore skin barrier function, as IFN-γ induces upregulation of components of the stratum corneum [19]. Restoration of the barrier function of the skin prevents aeroallergens and pathogens from penetrating the skin and causing additional inflammation. Additionally, CD8+ T-cells can prevent infection of the lesions with pathogens by killing pathogens and infected cells. S. Aureus is well known to cause superinfection in AD patients, which causes enhanced inflammation and disease. In conjunction, S. Aureus toxins cause production of IgE, extra maturation of Th2 cells and also activation of eosinophils [63].    
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Figure 1. Production of IL-17 and IL-22 in Psoriasis (left) and Atopic Dermatitis (right). In the Th1 environment present in psoriasis, Th17 cells produce both IL-17 and IL-22 and IL-22 is also produced by Th22 cells. IL-17 and IL-22 combined give rise to Psoriasis symptoms. In AD, the Th2 environment blocks Th17 function. Thus, only IL-22 is produced by both Th22 and Tc22 cells and the lack of IL-17 gives rise to symptoms specific for AD [31]. 

Figure 2. Indirect effect of CD8+ T-cells on IgE production of B-cells in asthma. The CD8+ T-cells trigger DCs to produce IL-12 and IL-18, which induces naïve CD4+ T-cells to maturate into Th1 cells. IFN-γ from these Th1 cells attenuates IgE production by B-cells [18].

Figure 3. Schematic overview of the processes CD8+ T-cells could influence that affect tissue damage in AD lesions. They prevent tissue damage by killing pathogens and promoting tissue repair via IFN-γ. CD8+ Tregs might kill eosinophils, indirectly preventing tissue damage. In conjunction, CD8+ T-cells promote tissue damage directly by inducing apoptosis of skin cells and indirectly by activating mast-cells and blocking skin cell differentiation. 
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